Adela, Inc. files Form D for $12 million convertible note offering

Adela, Inc. filed a Form D with the Securities and Exchange Commission dated October 19, 2026, disclosing a securities offering tied to a first sale date of October 2, 2026. The company, formerly known as DNAMx, Inc., is a Delaware corporation based at 353 Hatch Drive in Foster City, California.¹

The offering consists of convertible promissory notes that convert into equity securities of the issuer, along with the equity securities to be issued upon such conversion.¹ The total offering amount was $12,000,000, and the company reported that the full $12,000,000 had already been sold, leaving nothing remaining to be sold.¹ A total of five investors had participated in the offering as of the filing.¹

The offering was made under the Rule 506(b) exemption.¹ The minimum investment accepted from any outside investor was listed as $0.¹ The filing reported no sales commissions and no finders' fees.¹ The company stated the offering was not made in connection with a business combination transaction such as a merger or acquisition.¹

The filing names Lindsay Mateo as both an executive officer and director, and lists David Bonita, Paul Brown, Maneesh Jain, Robert Weisskoff, and Abraham Kometz as directors, Daniel Diniz De Carvalho, Anne-Renee Hartman, and Alan Williams as executive officers, and David Scheer as both an executive officer and director. The notice was signed by Lindsay Mateo, Chief Executive Officer of Adela, Inc., on October 19, 2026.¹ The company classified its industry group as biotechnology within health care.¹